Finotonlimab

Phase 2Monoclonal antibody

TTang-Du Hospital

Finotonlimab is one of 10 therapeutic programs targeting Head Neck Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Head Neck CancerNot yet recruiting

Head Neck CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

9 competitors in Head Neck Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

3 2

Keytruda

Merck & Co.

Phase 2

2 3

Beyfortus

BeiGene

Phase 2

1 4

Abraxane

Bristol-Myers Squibb

Phase 2

1 5

Vectibix

Amgen

Phase 2

1 6

Paraplatin

AAvyxa

Phase 2

2 7

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 2

2 8

Finotonlimab

TTang-Du Hospital

Phase 2

1 9

CD-001

CCD (Suzhou) Biopharma Co., Ltd.

Phase 1

1 10

SL-28.

SSecond Life Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 2Not yet recruiting

Head Neck Cancer

NCT07752394

Clinical

Trials by Indication[1]

Head Neck Cancer1 trial

Efficacy and Safety of Penpulimab Combined With Chemotherapy as Neoadjuvant Therapy in Patients With Locally Advanced Hypopharyngeal Carcinoma

Not yet recruiting·TTang-Du Hospital·Phase 2·NCT07752394·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Finotonlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Finotonlimab. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tang-Du Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody
Highest Phase: Phase 2[1]
Company: TTang-Du Hospital

Finotonlimab

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Head Neck Cancer1 trial

References

Drug Info

Quick Facts

Related News